Iloperidone not checked
Vanda Pharmaceuticals · VYV-683
FollowEvery change as it happens, and a Monday email
Trials
3 active
8 in total
What this is
- How it works
- Atypical Antipsychotic FDA class
- Tested for
- Schizophrenia (2 trials), Bipolar I Disorder, Hypertension, Uncontrolled Hypertension
- Main trialPhase 4
- “To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.”In the company’s words, NCT05648591 on ClinicalTrials.gov
- Other names
- Fanapt · VYV-683
Other drugs for Schizophrenia
- CariprazineAbbVie · Phase 3
- EvenamideNewron Pharmaceuticals SPA · Phase 3
- LB-102LB Pharmaceuticals Inc. · Phase 3
- B2227Bostal Drug Delivery Co., Ltd · Phase 2/3
- Brexpiprazole for ER injectionBostal Drug Delivery Co., Ltd · Phase 2/3
- LYBALVIAlkermes, Inc. · Phase 3
Coming up2
- Nov 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Dec 2028Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 31 Dec 2028 | Safety and Tolerability of Open-Labeled Iloperidone in Adolescents | |
| Phase 3Recruiting | Nov 2027 | Randomized Withdrawal Study in Patients With Schizophrenia | |
| Phase 2Recruiting | Oct 2026 | Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension | |
| Phase 3Completed | 26 Sep 2006 | Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia | |
| Phase 3Completed | Mar 2014 | Relapse Prevention Study in Patients With Schizophrenia | |
| Phase 3Completed | 7 Sep 2022 | Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder | |
| Phase 2Withdrawn | Nov 2023 | A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis | |
| Phase 1Completed | 30 Aug 2022 | A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026